See more : 1957 & Co. (Hospitality) Limited (8495.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Vivani Medical, Inc. (VANI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vivani Medical, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Megasoft Limited (MEGASOFT.BO) Income Statement Analysis – Financial Results
- Feng Tay Enterprises Co., Ltd. (9910.TW) Income Statement Analysis – Financial Results
- Acerinox, S.A. (ACX.VI) Income Statement Analysis – Financial Results
- Hudson Executive Investment Corp. (HECCW) Income Statement Analysis – Financial Results
- Viva Wine Group AB (VIVA.ST) Income Statement Analysis – Financial Results
Vivani Medical, Inc. (VANI)
About Vivani Medical, Inc.
Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 3.38M | 6.90M | 7.96M | 3.99M | 8.95M | 3.40M | 1.56M | 1.37M |
| Cost of Revenue | 357.00K | 381.00K | 345.00K | 167.00K | 2.15M | 4.89M | 7.75M | 9.35M | 4.30M | 3.56M | 5.63M | 4.40M |
| Gross Profit | -357.00K | -381.00K | -345.00K | -167.00K | 1.23M | 2.01M | 211.00K | -5.36M | 4.65M | -160.28K | -4.06M | -3.03M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 36.31% | 29.12% | 2.65% | -134.60% | 51.93% | -4.72% | -259.72% | -221.58% |
| Research & Development | 16.97M | 14.17M | 11.00M | 6.87M | 16.50M | 10.21M | 7.99M | 5.35M | 3.04M | 5.04M | 3.25M | 3.05M |
| General & Administrative | 10.00M | 7.07M | 2.32M | 2.38M | 9.23M | 10.69M | 10.93M | 10.08M | 8.22M | 6.57M | 4.17M | 4.03M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 6.10M | 11.34M | 9.57M | 8.99M | 8.94M | 6.84M | 3.30M | 2.19M |
| SG&A | 10.00M | 7.07M | 2.32M | 2.38M | 15.33M | 26.63M | 23.56M | 21.77M | 20.67M | 13.41M | 7.47M | 6.22M |
| Other Expenses | 0.00 | 475.00K | -91.00K | -36.00K | 3.35M | 4.60M | 2.64M | -727.00K | -991.00K | 2.62M | 3.22M | 3.73M |
| Operating Expenses | 26.97M | 21.24M | 13.32M | 9.24M | 31.82M | 36.83M | 28.92M | 27.85M | 24.70M | 21.07M | 13.93M | 12.99M |
| Cost & Expenses | 26.97M | 21.24M | 13.32M | 9.24M | 33.98M | 41.72M | 36.67M | 37.20M | 29.00M | 24.63M | 19.56M | 17.39M |
| Interest Income | 0.00 | 0.00 | 0.00 | 16.00K | 362.00K | 86.00K | 93.00K | 31.00K | 2.00K | 9.11K | 7.45K | 7.51K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.00K | 7.03M | 5.01M | 267.03K |
| Depreciation & Amortization | 357.00K | 381.00K | 345.00K | 167.00K | 414.00K | 435.00K | 457.00K | 432.00K | 335.00K | 279.18K | 315.77K | 324.71K |
| EBITDA | -26.61M | -19.16M | -12.98M | -8.89M | -33.18M | -34.66M | -28.06M | -32.75M | -19.68M | -27.89M | -17.64M | -15.69M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -893.25% | -498.69% | -354.75% | -822.53% | -220.25% | -820.75% | -1,127.18% | -1,147.39% |
| Operating Income | -26.97M | -21.24M | -13.32M | -9.24M | -30.60M | -34.83M | -28.71M | -33.21M | -20.05M | -21.23M | -18.00M | -16.02M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -905.50% | -505.00% | -360.48% | -833.38% | -223.99% | -624.91% | -1,150.05% | -1,171.82% |
| Total Other Income/Expenses | 1.31M | 7.35M | 550.00K | -36.00K | -3.00M | -269.00K | 193.00K | 31.00K | 29.00K | -13.97M | -4.97M | -257.74K |
| Income Before Tax | -25.65M | -13.89M | -12.77M | -9.28M | -33.59M | -35.09M | -28.52M | -33.18M | -20.02M | -35.20M | -22.97M | -16.28M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -994.14% | -508.90% | -358.06% | -832.60% | -223.66% | -1,035.99% | -1,467.73% | -1,190.67% |
| Income Tax Expense | 0.00 | -7.35M | -641.00K | 147.70K | 362.00K | 86.00K | 93.00K | 31.00K | 58.00K | -6.93M | 42.22K | 9.29K |
| Net Income | -25.65M | -6.54M | -12.13M | -9.28M | -33.59M | -35.09M | -28.52M | -33.18M | -20.02M | -35.20M | -22.97M | -16.28M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -994.14% | -508.90% | -358.06% | -832.60% | -223.66% | -1,035.99% | -1,467.73% | -1,190.67% |
| EPS | -0.50 | -0.17 | -1.10 | -1.35 | -6.85 | -12.69 | -12.64 | -20.13 | -13.48 | -10.31 | -4.87 | -3.45 |
| EPS Diluted | -0.50 | -0.17 | -1.10 | -1.35 | -6.85 | -12.69 | -12.64 | -20.13 | -13.48 | -10.31 | -4.87 | -3.45 |
| Weighted Avg Shares Out | 50.85M | 38.24M | 11.03M | 6.86M | 4.90M | 2.77M | 2.26M | 1.65M | 1.48M | 3.41M | 4.72M | 4.72M |
| Weighted Avg Shares Out (Dil) | 50.85M | 38.24M | 11.03M | 6.86M | 4.90M | 2.77M | 2.26M | 1.65M | 1.48M | 3.41M | 4.72M | 4.72M |
Vivani Medical Surges on its Ozempic-Like Weight-Loss Implant
The Ozempic craze continues to make headlines in the medical sector, and GLP-1 drug stocks continue to surge higher. Shares of Ozempic and Wegovy makers Novo Nordisk A/S NYSE: NVO are already up 20% year-to-date (YTD).
Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants, today announced that it has entered into a securities purchase agreement with an institutional investor to purchase 3,947,368 shares...
Vivani Medical (VANI) stock price surged: is it a good buy?
Vivani Medical (NASDAQ: VANI) stock price surged hard this week after the company published positive results of its ongoing weight loss drug trial. The shares surged from about $1 and reached a high of $7.81.
Why Is Vivani Medical (VANI) Stock Up 300% Today?
Little-known emerging biopharmaceutical company Vivani Medical (NASDAQ: VANI ) saw its market value increase dramatically on Wednesday. Catapulting sentiment was the company's weight-loss solution, which offered compelling results compared to mainline weight-loss therapeutics.
Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic®/Wegovy® and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants, today announced positive preclinical data on weight loss effects for NPM-115, the Company's miniature, twice-yearly, exenatide implant under development...
Vivani Medical Provides Business Update and Reports Third Quarter Financial Results
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants, today reported financial results for the third quarter of 2023 and provided a business update. Vivani™ continues to advance...
Vivani Medical to Present at BIO Investor Forum
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative, preclinical-stage biopharmaceutical company that develops novel, long-term drug implants, announced today that it will present at the BIO Investor Forum at 2:00 p.m. PDT at the Hilton...
Vivani Medical to Present at the Boulder Peptide Symposium
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative, preclinical-stage biopharmaceutical company that develops novel, long-term drug implants, announced today that it will present at the upcoming Annual Boulder Peptide Symposium at 11:20 am PST at...
Vivani Medical Subsidiary Cortigent to Present Orion Clinical Study Results at The Eye and The Chip World Research Congress on Artificial Vision October 8-10
EMERYVILLE, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants, announced today that its wholly-owned subsidiary Cortigent, Inc., a company pioneering targeted neurostimulation technology to recover critical body functions, will present the Early...
Vivani Medical Reports Second Quarter Financial Results and Provides Business Update
EMERYVILLE, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants, today reported financial results for the second quarter of 2023 and provided a business update. Vivani™ continues to advance...
Source: https://incomestatements.info
Category: Stock Reports